Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg positive for more than 6 months~* HBeAg positive~* ALT≥80U/L or inflammation score ≥2 of histological examination~Exclusion Criteria:~* History of drug allergy to GM-CSF~* coinfection with HCV, HIV, HAV, HEV~* liver cirrhosis or CHILD score \>7~* diagnosis of hepatocellular carcinoma or AFP\>100ng/ml~* Allergic thrombocytopenic purpura

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ETV+GM-CSF (Type: EXPERIMENTAL): Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
- ETV monotherapy (Type: ACTIVE_COMPARATOR): As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.

Based on this trial design, predict the completion outcome and termination type (if applicable).